Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Kreft, Sophia [VerfasserIn]   i
 Gesierich, Anja [VerfasserIn]   i
 Eigentler, Thomas [VerfasserIn]   i
 Franklin, Cindy [VerfasserIn]   i
 Valpione, Sara [VerfasserIn]   i
 Ugurel, Selma [VerfasserIn]   i
 Utikal, Jochen [VerfasserIn]   i
 Haferkamp, Sebastian [VerfasserIn]   i
 Blank, Christian [VerfasserIn]   i
 Larkin, James [VerfasserIn]   i
 Garbe, Claus [VerfasserIn]   i
 Schadendorf, Dirk [VerfasserIn]   i
 Lorigan, Paul [VerfasserIn]   i
 Schilling, Bastian [VerfasserIn]   i
Titel:Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma
Verf.angabe:Sophia Kreft, Anja Gesierich, Thomas Eigentler, Cindy Franklin, Sara Valpione, Selma Ugurel, Jochen Utikal, Sebastian Haferkamp, Christian Blank, James Larkin, Claus Garbe, Dirk Schadendorf, Paul Lorigan, Bastian Schilling
E-Jahr:2019
Jahr:15 June 2019
Umfang:9 S.
Fussnoten:Gesehen am 28.08.2019
Titel Quelle:Enthalten in: European journal of cancer
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1992
Jahr Quelle:2019
Band/Heft Quelle:116(2019), Seite 207-2154
ISSN Quelle:1879-0852
Abstract:Objectives - Targeted therapy (TT) is an effective treatment for advanced BRAFV600-mutated melanoma, but most patients eventually acquire resistance and progress. Here, we evaluated the outcome of second-line immune checkpoint blockade (ICB) after progression on dual BRAF and MEK inhibition. - Methods - Patients with metastatic melanoma progressing on combined BRAF + MEK inhibition and receiving second-line ICB between 2015 and 2019 in 9 tertiary referral centres were enrolled. Demographic and clinical data and blood counts of all patients were collected retrospectively. - Results - We identified 99 patients with stage IV melanoma receiving ICB (nivolumab, pembrolizumab [n = 39] or ipilimumab plus nivolumab [n = 60]) after progression on combined TT. The median progression-free survival was similar in the PD-1 and ipilimumab plus nivolumab group (2.6 months [95% confidence interval {CI}, 2.0-3.1] vs. 2.0 [95% CI, 1.4-2.6], p = 0.15). The objective response rate was 18.0% in the PD-1 and 15.0% in the ipilimumab plus nivolumab group (p = 0.70). The disease control rate was 25.7% for monotherapy and 18.3% for combined ICB (p = 0.39). The median overall survival was 8.4 months (95% CI, 5.1-11.7) for patients receiving PD-1 monotherapy and 7.2 months (95% CI, 5.2-9.1) for patients receiving ipilimumab plus nivolumab (p = 0.86). The latter was associated with a higher rate of treatment-related adverse events (AEs). No significant association of laboratory values or clinicopathological characteristics with response to second-line ICB was observed. - Conclusions - PD-1 monotherapy and combined ipilimumab plus nivolumab show similar activity and outcome in patients with melanoma resistant to BRAF + MEK inhibition. However, combined ipilimumab plus nivolumab was associated with a higher rate of treatment-related AEs compared with monotherapy.
DOI:doi:10.1016/j.ejca.2019.05.015
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.ejca.2019.05.015
 Volltext: http://www.sciencedirect.com/science/article/pii/S0959804919303181
 DOI: https://doi.org/10.1016/j.ejca.2019.05.015
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Ipilimumab
 MAPK
 Melanoma
 PD-1
 Second-line treatment
K10plus-PPN:1672357454
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68424811   QR-Code
zum Seitenanfang